Physician profile
Mark T Roznik
NPI 1184698482
$305.33
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $46.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.23 | 2019 | |
| Merck Sharp & Dohme LLC | $37.65 | 2019 | |
| Astellas Pharma US INC | $34.76 | 2019 | |
| Amgen INC. | $17.74 | 2019 | |
| Lilly USA, LLC | $17.72 | 2019 | |
| Shire North American Group INC | $14.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.94 | 2019 | |
| Pfizer INC. | $14.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.37 | 2019 | |
| Vanda Pharmaceuticals INC. | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.